Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04072458
Other study ID # BP1002-101-Lymph
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 5, 2020
Est. completion date January 2026

Study information

Verified date February 2024
Source Bio-Path Holdings, Inc.
Contact Michael Hickey
Phone 832-742-1361
Email mhickey@biopathholdings.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date January 2026
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults =18 years of age 2. Patient has a life expectancy = 3 month 3. Patient has relapsed or refractory disease Relapsed lymphoma: Relapsed lymphoma is disease that has responded to treatment but then returns. Refractory lymphoma: Failure to achieve complete response at the end of therapy or progression within 6 months from completion of therapy 4. Included Diseases - DLBCL, including transformed lymphoma - Mantle Cell Lymphoma - PTCL - CTCL - CLL/SLL - Follicular lymphoma - Marginal zone lymphoma - Hodgkin lymphoma (both classical and lymphocyte predominant) - Waldenströms Macroglobulinemia 5. Must has failed or is not a candidate for available therapies with reasonable likelihood of clinical benefit, which includes FDA approved products and standard of care regimens 6. Therapy means at least three front lines of therapy including Hematopoeitic Stem Cell Transplant (HSCT and/or Chimeric Antigen Receptor (CAR) T cells, when applicable 7. Females must be of non-childbearing potential, surgically sterile, postmenopausal, or practice adequate methods of contraception during the study 8. Males must agree to use an adequate method of contraception during the study 9. Eastern Cooperative Oncology Group (ECOG) Performance score of 0, 1, or 2 10. Adequate hepatic and renal functions as defined by: - Aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 times the upper limit of normal (ULN); and - Total bilirubin =1.5 times ULN; and - Estimated glomerular filtration rate (eGFR) of at least 50ml/min. These estimations can be calculated using the following methods: - Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation - Cockcroft Gault equation - Modification of Diet in Renal Disease (MDRD study equation) - Creatinine clearance estimated by 24-hr urine collection for creatinine clearance 11. Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment 12. Willing and able to provide written informed consent Exclusion Criteria: 1. Active non-hematologic malignancy other than lymphoid malignancies treated with immuno- or chemotherapy within the previous 12 months except active non-melanoma, non-invasive skin cancer will be allowed 2. Known, active Central Nervous System (CNS) involvement of disease requiring intrathecal therapy. Note: Patients with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening 3. Patient eligible for high dose chemotherapy and autologous stem cell transplant 4. Indolent non-Hodgkin lymphoma (iNHL) 5. Patients at high risk of Tumor Lysis Syndrome (TLS) a. Bulky disease i. A unidimensional lesion greater than 10 cm and/or b. Lymphocyte count greater than 25,000 per µL 6. Receipt of any anti-cancer therapy within 14 days prior to Cycle 1 Day 1 (C1D1) 7. Uncontrolled active, untreated, or progressive infection 8. Receipt of any investigational agent or on study treatment within 30 days prior to C1D1 9. Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug 10. Serious intercurrent medical or psychiatric illness which, in the opinion of the Investigator, would interfere with the ability of the participant to complete the study 11. Active hepatitis B infection (based on positive surface antigen [HBsAg]), hepatitis C infection (based on Hepatitis C Virus (HCV) positive antibody [HCV Ab]), or human immunodeficiency virus (HIV-1 or HIV-2, based on positive antibody) 12. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia or clinically significant baseline EKG abnormality (e.g., QTcF >470 msec) 13. Within the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack 14. Uncontrolled seizure disorder 15. Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason.

Study Design


Intervention

Drug:
L-Bcl-2 antisense oligonucleotide
There will be 2 planned dose levels, 20, and 40 mg/m^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.

Locations

Country Name City State
United States Georgia Cancer Center Augusta Georgia
United States University of Texas Southwestern Medical Center Dallas Texas
United States MD Anderson Cancer Research Center Houston Texas
United States Sarah Cannon Research Institute/Tennesee Oncology Nashville Tennessee
United States New York Medical College / Westchester Medical Center Valhalla New York

Sponsors (1)

Lead Sponsor Collaborator
Bio-Path Holdings, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory objective to correlate treatment response with cytogenetic characteristics Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression 30 days
Other Exploratory objective to correlate treatment response with molecular characteristics Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression 30 days
Primary Identify Dose Limiting Toxicity (DLT) of BP1002 Identify DLT of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria 30 days
Primary Identify and grade treatment-emergent adverse events (TEAE) of escalating doses of BP1002 Identify TEAE of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria 30 days
Primary Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002 by identification and grading of Identify and grade treatment-emergent laboratory abnormalities of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria 30 days
Primary Identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) of escalating doses of BP1002 Collection of 12-lead EKGs at defined intervals to identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) 30 days
Primary Recommended Phase 2 dose (RP2D) of BP1002 Determine RP2D by evaluating Maximally Tolerated Dose (MTD) data: Any Dose Limiting Toxicity (DLT) observed will trigger an expansion of a cohort from 3 to 6 patients. A second DLT at any dose level will identify the Maximum Dose. The dose below that will be the MTD. 210 days
Primary Determine plasma pharmacokinetics (PK) of BP1002 using maximum plasma drug concentration Evaluate in vivo PK of BP1002 using maximum plasma drug concentration (Cmax) 30 days
Primary Determine plasma pharmacokinetics (PK) of BP1002 using volume of distribution Evaluate in vivo PK of BP1002 volume of distribution (Vd) 30 days
Primary Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant Evaluate in vivo PK of BP1002 elimination rate constant 30 days
Primary Determine half-life plasma pharmacokinetics (PK) of BP1002 Evaluate in vivo PK of BP1002 half-life (t1/2) 30 days
Primary Determine pharmacokinetics (PK) of BP1002 12-lead EKG assessments will be collected and analyzed for conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) from those the EKG obtained immediately before the first BP1002 dose, and after BP1002 dose, and will mirror the time points used to collect the plasma PK assessments 30 days
Secondary Determine evidence of tumor response by bone marrow aspirate Assess tumor response by evaluating bone marrow aspirate to determine complete response (CR), partial response (PR), or minor response (MR) using appropriate uniform response criteria as published by Response Evaluation Criteria in Lymphoma (RECIL) 2017, CLL guidelines, and International Workshop on Waldenström's Macroglobulinemia (IWWM 6th) 30 days
Secondary Determine evidence of tumor response by Complete Blood Count (CBC) Assess tumor response by evaluating CBC measurements to determine complete response (CR), partial response (PR), or minor response (MR) using appropriate uniform response criteria as published by Response Evaluation Criteria in Lymphoma (RECIL) 2017, CLL guidelines, and International Workshop on Waldenström's Macroglobulinemia (IWWM 6th) 30 days
Secondary Determine estimates for time to progression (TTP) Measured from treatment start date to date of progression by CBC and/or bone marrow aspirate 30 days
Secondary Determine estimates for progression-free survival (PFS) Measured from treatment start date to date of progression or death by CBC and/or bone marrow aspirate 30 days
Secondary Determine estimates for event-free survival (EFS) Measured from treatment start date to date of progression, death, or change in therapy by CBC and/or bone marrow aspirate 30 days
Secondary Activity of BP1002 on Bcl-2 expression in tumor samples Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression using patient blood samples 30 days
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05976763 - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Phase 3
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Recruiting NCT05471843 - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05076097 - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT03891355 - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL Phase 2
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT01665768 - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Phase 2
Completed NCT01437709 - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant Phase 2
Completed NCT00963534 - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Phase 1/Phase 2
Completed NCT00921414 - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Phase 3
Withdrawn NCT00541424 - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma N/A
Completed NCT01456351 - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Phase 3
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Completed NCT03295240 - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Early Phase 1